a preventable and treatable disease characterised by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking.
Although COPD affects the lungs, it also produces significant systemic consequences. 1 COPD is a disease of ageing associated with smoking, reduced physical activity, an adverse early life environment and lower socioeconomic status. As such, it shares many risk factors with other chronic conditions which frequently cooccur. Some studies have found comorbidities more common in advanced disease but this has not been a universal finding. 2 The occurrence of comorbidities could represent a common susceptibility to risk factors or a systemic 'overspill' of lung inflammation having a direct effect on remote disease processes such as atherosclerosis. 3 These two mechanisms are not mutually exclusive.
This review describes some of the important extrapulmonary features of COPD relevant to the management of patients with the disease (Table 1) 
Skeletal muscle
Skeletal muscle weakness is a common complication of COPD, and is associated with reduced functional exercise capacity, impaired quality of life (Fig 1) and increased mortality. 4, 5 Cachexia is a well recognised feature of the end stage of many chronic diseases but it is less well appreciated that skeletal muscle weakness is a common feature of early COPD. 6 This is likely to be due to reduced physical activity, which is itself a risk factor for the development of COPD. 7, 8 The quadriceps, one of the main weight-bearing muscles, has been most extensively studied in patients with COPD. This typically displays fibre atrophy and a shift from type I, fatigue resistant, oxidative fibres towards a type II, glycolytic pattern manifest as a reduction in both strength and endurance. 9 The importance of skeletal muscle is highlighted by the effect of pulmonary rehabilitation which produces dramatic increases in functional capacity and health status without changing lung function. 5, 10 Disuse is the main driver for muscle weakness in COPD, but other factors have been implicated including hypoxia, systemic inflammation, corticosteroids and genetic susceptibility. 11 Exacerbations of COPD accentuate many of these factors and are associated with an acute loss of skeletal muscle strength which may not recover. 12 Loss of fat free mass over time is associated with exacerbation rate. 13 Recent data show that provision of pulmonary rehabilitation early after an exacerbation can restore function, with a number needed to treat of only four to prevent one readmission. [14] [15] [16] Reduced inspiratory muscle pressures are also common in COPD. These occur largely as a consequence of hyperinflation which flattens and shortens the diaphragm, placing it at a mechanical disadvantage, rather than because of intrinsic muscle problems. 20, 21 and hyperinflation. 22 Systemic inflammation, a consistent finding in COPD, is associated with the development of atherosclerosis. An analysis of data from primary care found that a diagnosis of COPD was associated with a 10.1-fold increase in risk of myocardial infarction and a 3.4-fold risk of stroke. 23 Acute exacerbations of COPD are a high risk period with raised troponin, an indication of cardiac damage, occurring frequently and associated with increased mortality. 24 COPD has direct effects on cardiac function. Hyperinflation with the development of raised intrathoracic pressures reduces cardiac filling and impairs cardiac output. 25 Low cardiac output leads to reduced mixed venous saturations, accentuating the effects of ventilation perfusion mismatch in damaged lung. In some patients destruction of the pulmonary vascular network causes right ventricular hypertrophy (cor pulmonale). It should be noted that fluid retention in the context of hypoxia and COPD is also driven by renal mechanisms.
It remains to be established whether the appropriate response in COPD patients is to look systematically for cardiovascular risk factors and treat them aggressively, or whether a more blanket 'population' approach deploying strategies known to reduce cardiovascular events (eg statins, angiotensin-converting enzyme inhibitors, betablockers) is justified, regardless of the presence of cardiovascular disease.
Osteoporosis
Smoking, low physical activity levels, corticosteroid treatment and systemic inflammation are risk factors for osteoporosis. Osteoporosis is highly prevalent in both men and women with COPD. 26 It is associated with poor nutrition and reduced time spent outdoors. Both these factors contribute to low vitamin D levels, as noted in several cross-sectional studies of COPD. 27 Vitamin D is important for bone health as well as having an impact on inflammatory processes. Several trials of supplementation in COPD are ongoing. Osteoporotic vertebral collapse is a particular issue in COPD because it reduces thoracic volume and can thus limit ventilatory capacity. Consideration of bone health should be a routine part of the assessment of patients with COPD; improving physical activity and smoking cessation are key in this area. 
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Peripheral neuropathy (including increased phrenic nerve conduction time) is common in COPD and increased excitability of the diaphragm motor cortex has been reported. 28, 29 Muscle cramps are a frequent complaint raised by COPD patients in clinical practice, but few published data are available beyond their known association with longacting bronchodilators.
Mild cognitive impairment related to hypoxia has been described in COPD and may particularly affect information processing and verbal memory. This can have consequences for the understanding and use of self-management plans and the introduction of new devices during acute exacerbations. 30 Depression is also a common feature, thought to be mainly reactive to the limitations and discomfort of the disease, without any specific features. The recent National Institute for Health and Clinical Excellence (NICE) quality standards for COPD recommend systematic use of a tool such as the Hospital Anxiety and Depression Score as part of an annual 'comprehensive clinical and psychosocial assessment'. Treatment for depression is conventional, with exercise, talking therapies and pharmacotherapies, as appropriate. An overlap between anxiety and breathlessness can be addressed through pulmonary rehabilitation and learning techniques for breathing control such as pursed lip breathing.
Other problems
Gastro-oesophageal reflux (GORD) is a common feature of respiratory disease, perhaps because diaphragm flattening impairs the function of the gastrooesophageal sphincter. Interestingly, symptoms of GORD were associated with frequent exacerbations in the ECLIPSE cohort. 31 Anaemia of chronic disease occurs in about 10% of patients with COPD and is associated with worse quality of life and impaired survival. 32 
Conclusions
Patients with COPD are likely to have a range of pathologies outside the lung, acknowledged in national and international guidelines as well as in the recently published NICE quality standards for COPD. These extrapulmonary consequences need to be considered, evaluated and treated systematically, though further data are needed to identify the best strategies to pursue for screening, investigation and treatment.
